ストックスクリーナーアプリを入手
8.14
1.09%
-0.09
アフターアワーズ：
8.14
Arcturus Therapeutics Holdings Inc (ARCT) 最新ニュース
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of "Moderate Buy" by Brokerages - marketbeat.com
Liquidity Mapping Around (ARCT) Price Events - Stock Traders Daily
We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Moomoo
Dimensional Fund Advisors LP Decreases Holdings in Arcturus Therapeutics Holdings Inc. $ARCT - marketbeat.com
HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings - marketbeat.com
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline - marketbeat.com
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9 - Moomoo
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen - marketbeat.com
Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat
A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $20 to $20 - Moomoo
Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside - TradingView
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress - BioSpace
ARCT Looks 57.9% Overvalued on GF Value™ - GuruFocus
Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view By Investing.com - Investing.com South Africa
Arcturus Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view - Investing.com
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary - TradingView
Q2 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript - GuruFocus
Arcturus Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Arcturus Therapeutics reports Q2 2026: $3.0M revenue, $23.8M net loss, $191.5M cash - TradingView
Arcturus Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Why (ARCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Q2 2026 -- GF Value Sees 44% Downside - Yahoo Finance
Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a shareEarnings Preview - TradingView
Arcturus Therapeutics (NASDAQ:ARCT) Downgraded to "Strong Sell" Rating by Wall Street Zen - marketbeat.com
Arcturus Therapeutics (ARCT) to Announce Quarterly Earnings on Thursday - marketbeat.com
Arcturus Therapeutics Q2 Results: Financials and update due Aug 6 - scanx.trade
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026 - Yahoo Finance
Arcturus Therapeutics Holdings Inc - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Cash Flow - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
ARCT|Arcturus Therapeutics Holdings Inc|Price:5.530|Chg%:-0.260 - TradingKey
Arcturus Therapeutics Holdings Inc. Revenue Breakdown – NASDAQ:ARCT - TradingView
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
Arcturus Therapeutics Holdings Inc (ARCT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Amova Asset Management Americas Inc. Grows Stock Holdings in Arcturus Therapeutics Holdings Inc. $ARCT - marketbeat.com
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - BioSpace
Arcturus: Now That It's Come This Low, It's Time To Buy And Hold (NASDAQ:ARCT) - Seeking Alpha
Arcturus Therapeutics (ARCT) Q1 2026 Earnings: Loss Narrows as Pipeline Progress Offsets Revenue Absence - dars.gov.et
Arcturus Therapeutics Holdings Inc (ARCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Understanding Momentum Shifts in (ARCT) - Stock Traders Daily
Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis - Kavout | AI
ARCT Should I Buy - intellectia.ai
Arcturus Therapeutics (ARCT) Q1 2025 earnings summary - Quartr
Arcturus Therapeutics (ARCT) Surges 5.66% as Stock Bounces Off SupportComposite Profile - dars.gov.et
Price to sales forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
If You Invested $1,000 in Arcturus Therape (ARCT) - Stock Titan
ARCTArcturus Therapeutics Holdings Inc Latest SEC Filings - Finviz
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? - Yahoo Finance
This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial - Yahoo Finance
ARCT Initiates Coverage by Freedom Broker -- Rating Set to Buy - GuruFocus
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):